Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
about
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerAnalysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancerVinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.Development of Targeted Therapies in ErbB2-Positive Breast CancerThe Role of Targeted Agents in the Treatment of Metastatic Breast Cancer.Immunological Approaches in the Treatment of Metastasized Breast CancerSustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report.HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?Trastuzumab-based combination therapy for breast cancer.Treatment of HER2-positive metastatic breast cancer following initial progression.Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer.Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.Treatment options for breast cancer resistant to anthracycline and taxaneWhich patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Trastuzumab in the management of early and advanced stage breast cancer.Role of trastuzumab in the management of HER2-positive metastatic breast cancer.HER2-positive gastric cancer.Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.HER2 directed therapy for gastric/esophageal cancers.Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.Treatment beyond progression: is it moving from belief to evidence?Cardiotoxicity related to long-term trastuzumab therapy in metastatic breast cancer: the potential role of treatment duration and cardiac risk factors.Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer
P2860
Q24656159-079DEAF8-ECEE-4C61-9ACD-AB2AEEDC9232Q33236634-3C21B0DB-B716-498A-9FB2-D5FE514AC7C3Q33257718-8BEBF593-F3B9-48EF-A879-CD3473C65B24Q33354783-8FC02549-6F46-42C1-B0AC-74724A4CDEBBQ33511035-7E26AB7B-6368-4C39-9FD3-ACE9D08F7B7EQ34095743-2AD74B9D-2F88-4391-8495-8AFB2E6B3B4FQ34096063-49EADA1C-2BE3-4913-B0F6-594512C1F6F2Q34140043-FA696204-8CAA-4680-B583-1F0644EFD9F4Q34419517-DD96149D-B192-4D55-BD74-DFD4EBF2437EQ34974436-F85E46EC-3710-4E8E-AC7A-CE88D412A65AQ35584206-FCD7F107-A56A-47B2-91F7-D42261874A9EQ35584899-345B8603-6C50-441A-B0AC-7F4A2CB82604Q35609686-89FF21D9-428E-4AB5-918F-C7A6A85EAC5AQ36275971-83377744-E1D9-43E1-A18B-5839B13E313AQ36451131-27924E93-41C2-431B-918D-BA286004A207Q36955091-86EAD9D6-1921-49A0-9A93-F74EDA6725E0Q37074153-AB5D33F7-0CA5-40A3-9B07-126BDF2CA317Q37140621-7D1412A6-884C-4EFB-999D-8143A24F3ED1Q37207961-4B8B4464-2513-4331-81DB-C45DD762CAEDQ37236305-3E880810-2156-40CF-B2F7-4219599B24C2Q37290613-90BD0D45-B8EC-4A4B-A1B7-39D4C9E0FF84Q37355370-B6E07C5F-49E4-4E74-89AD-88F4C9051E7FQ37468290-65A203BC-A605-4718-81DF-DEBE7796ADABQ37687375-DA250A52-0273-4ECA-BF96-8A984ED3DA90Q37725973-48BAC9E5-F230-41E9-A318-941FFEEE8BBDQ37970020-93C65201-3865-4FB8-A441-D36AF7A79AAEQ38210387-4ABD8A69-28BE-40D1-A937-410E59CF89ADQ38289356-ED0B27EB-2BE8-4586-A080-B1B3F17268FDQ38707852-6C196593-D751-4E66-9333-CA231EDEE4BCQ42995231-852D6524-E327-4FF1-AF14-8B68C89C8186Q53577184-CB26779D-D40E-45B8-8386-E8377EE4E437Q54368881-3EB4087E-4058-4920-B4C1-93E08AE70CB2Q58849543-0DB6BF75-113D-4871-9040-0C3237888516
P2860
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Continuation of trastuzumab be ...... ic cooperative oncology group.
@ast
Continuation of trastuzumab be ...... ic cooperative oncology group.
@en
type
label
Continuation of trastuzumab be ...... ic cooperative oncology group.
@ast
Continuation of trastuzumab be ...... ic cooperative oncology group.
@en
prefLabel
Continuation of trastuzumab be ...... ic cooperative oncology group.
@ast
Continuation of trastuzumab be ...... ic cooperative oncology group.
@en
P2093
P356
P1476
Continuation of trastuzumab be ...... ic cooperative oncology group.
@en
P2093
Christos Christodoulou
Dimitrios Mavroudis
Dimitrios Tsavdaridis
Evangelia Razis
Helen Gogas
Maria Karina
Stefanos Labropoulos
Vassilios Georgoulias
P304
P356
10.3816/CBC.2003.N.017
P407
P577
2003-06-01T00:00:00Z